nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—ADRA1B—polycystic ovary syndrome	0.447	0.598	CbGaD
Paliperidone—ADRA1A—polycystic ovary syndrome	0.301	0.402	CbGaD
Paliperidone—Tonsillitis—Metformin—polycystic ovary syndrome	0.00528	0.0875	CcSEcCtD
Paliperidone—Body temperature decreased—Metformin—polycystic ovary syndrome	0.00238	0.0394	CcSEcCtD
Paliperidone—Hypothermia—Metformin—polycystic ovary syndrome	0.00238	0.0394	CcSEcCtD
Paliperidone—Risperidone—ADRA1B—polycystic ovary syndrome	0.00225	0.434	CrCbGaD
Paliperidone—Toothache—Metformin—polycystic ovary syndrome	0.00219	0.0363	CcSEcCtD
Paliperidone—Respiratory distress—Metformin—polycystic ovary syndrome	0.0021	0.0348	CcSEcCtD
Paliperidone—Upset stomach—Metformin—polycystic ovary syndrome	0.00203	0.0337	CcSEcCtD
Paliperidone—Risperidone—ADRA1A—polycystic ovary syndrome	0.00151	0.292	CrCbGaD
Paliperidone—Chest discomfort—Metformin—polycystic ovary syndrome	0.00151	0.025	CcSEcCtD
Paliperidone—Iloperidone—ADRA1A—polycystic ovary syndrome	0.00142	0.274	CrCbGaD
Paliperidone—Ear pain—Metformin—polycystic ovary syndrome	0.00113	0.0188	CcSEcCtD
Paliperidone—Nasal congestion—Metformin—polycystic ovary syndrome	0.00106	0.0176	CcSEcCtD
Paliperidone—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.000991	0.0164	CcSEcCtD
Paliperidone—Lethargy—Metformin—polycystic ovary syndrome	0.000987	0.0164	CcSEcCtD
Paliperidone—Pain in extremity—Metformin—polycystic ovary syndrome	0.000967	0.016	CcSEcCtD
Paliperidone—HTR2A—urine—polycystic ovary syndrome	0.000886	0.0744	CbGeAlD
Paliperidone—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000884	0.0146	CcSEcCtD
Paliperidone—Breast disorder—Metformin—polycystic ovary syndrome	0.000874	0.0145	CcSEcCtD
Paliperidone—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000865	0.0143	CcSEcCtD
Paliperidone—Influenza—Metformin—polycystic ovary syndrome	0.000836	0.0139	CcSEcCtD
Paliperidone—CYP3A4—urine—polycystic ovary syndrome	0.00082	0.0689	CbGeAlD
Paliperidone—Pancreatitis—Metformin—polycystic ovary syndrome	0.00082	0.0136	CcSEcCtD
Paliperidone—CYP2D6—urine—polycystic ovary syndrome	0.000807	0.0678	CbGeAlD
Paliperidone—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000802	0.0133	CcSEcCtD
Paliperidone—Neutropenia—Metformin—polycystic ovary syndrome	0.000782	0.013	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000777	0.0129	CcSEcCtD
Paliperidone—Infestation—Metformin—polycystic ovary syndrome	0.000745	0.0124	CcSEcCtD
Paliperidone—Infestation NOS—Metformin—polycystic ovary syndrome	0.000745	0.0124	CcSEcCtD
Paliperidone—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000705	0.0117	CcSEcCtD
Paliperidone—Bradycardia—Metformin—polycystic ovary syndrome	0.000681	0.0113	CcSEcCtD
Paliperidone—Rhinitis—Metformin—polycystic ovary syndrome	0.000671	0.0111	CcSEcCtD
Paliperidone—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000666	0.011	CcSEcCtD
Paliperidone—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000659	0.0109	CcSEcCtD
Paliperidone—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000658	0.0109	CcSEcCtD
Paliperidone—Eye disorder—Metformin—polycystic ovary syndrome	0.000625	0.0104	CcSEcCtD
Paliperidone—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000621	0.0103	CcSEcCtD
Paliperidone—Flushing—Metformin—polycystic ovary syndrome	0.000621	0.0103	CcSEcCtD
Paliperidone—Angiopathy—Metformin—polycystic ovary syndrome	0.000607	0.0101	CcSEcCtD
Paliperidone—Immune system disorder—Metformin—polycystic ovary syndrome	0.000604	0.01	CcSEcCtD
Paliperidone—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000603	0.01	CcSEcCtD
Paliperidone—Chills—Metformin—polycystic ovary syndrome	0.0006	0.00996	CcSEcCtD
Paliperidone—Malnutrition—Metformin—polycystic ovary syndrome	0.000583	0.00966	CcSEcCtD
Paliperidone—Erythema—Metformin—polycystic ovary syndrome	0.000583	0.00966	CcSEcCtD
Paliperidone—Flatulence—Metformin—polycystic ovary syndrome	0.000574	0.00952	CcSEcCtD
Paliperidone—Dysgeusia—Metformin—polycystic ovary syndrome	0.000571	0.00946	CcSEcCtD
Paliperidone—Muscle spasms—Metformin—polycystic ovary syndrome	0.00056	0.00929	CcSEcCtD
Paliperidone—Vision blurred—Metformin—polycystic ovary syndrome	0.000549	0.0091	CcSEcCtD
Paliperidone—Tremor—Metformin—polycystic ovary syndrome	0.000546	0.00905	CcSEcCtD
Paliperidone—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000541	0.00896	CcSEcCtD
Paliperidone—Malaise—Metformin—polycystic ovary syndrome	0.000525	0.00871	CcSEcCtD
Paliperidone—Syncope—Metformin—polycystic ovary syndrome	0.000522	0.00866	CcSEcCtD
Paliperidone—Palpitations—Metformin—polycystic ovary syndrome	0.000515	0.00854	CcSEcCtD
Paliperidone—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000512	0.00849	CcSEcCtD
Paliperidone—Hypertension—Metformin—polycystic ovary syndrome	0.000503	0.00834	CcSEcCtD
Paliperidone—Chest pain—Metformin—polycystic ovary syndrome	0.000496	0.00822	CcSEcCtD
Paliperidone—Myalgia—Metformin—polycystic ovary syndrome	0.000496	0.00822	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000493	0.00817	CcSEcCtD
Paliperidone—Discomfort—Metformin—polycystic ovary syndrome	0.00049	0.00812	CcSEcCtD
Paliperidone—Oedema—Metformin—polycystic ovary syndrome	0.000475	0.00788	CcSEcCtD
Paliperidone—Infection—Metformin—polycystic ovary syndrome	0.000472	0.00783	CcSEcCtD
Paliperidone—Shock—Metformin—polycystic ovary syndrome	0.000468	0.00776	CcSEcCtD
Paliperidone—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000466	0.00773	CcSEcCtD
Paliperidone—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000466	0.00772	CcSEcCtD
Paliperidone—Skin disorder—Metformin—polycystic ovary syndrome	0.000462	0.00766	CcSEcCtD
Paliperidone—Anorexia—Metformin—polycystic ovary syndrome	0.000453	0.00751	CcSEcCtD
Paliperidone—Hypotension—Metformin—polycystic ovary syndrome	0.000444	0.00737	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000433	0.00718	CcSEcCtD
Paliperidone—Paraesthesia—Metformin—polycystic ovary syndrome	0.000427	0.00708	CcSEcCtD
Paliperidone—Dyspnoea—Metformin—polycystic ovary syndrome	0.000424	0.00703	CcSEcCtD
Paliperidone—Somnolence—Metformin—polycystic ovary syndrome	0.000423	0.00701	CcSEcCtD
Paliperidone—Dyspepsia—Metformin—polycystic ovary syndrome	0.000419	0.00694	CcSEcCtD
Paliperidone—Decreased appetite—Metformin—polycystic ovary syndrome	0.000413	0.00685	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00041	0.00681	CcSEcCtD
Paliperidone—Fatigue—Metformin—polycystic ovary syndrome	0.00041	0.0068	CcSEcCtD
Paliperidone—Constipation—Metformin—polycystic ovary syndrome	0.000407	0.00674	CcSEcCtD
Paliperidone—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000392	0.0065	CcSEcCtD
Paliperidone—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000389	0.00645	CcSEcCtD
Paliperidone—Urticaria—Metformin—polycystic ovary syndrome	0.000378	0.00626	CcSEcCtD
Paliperidone—Abdominal pain—Metformin—polycystic ovary syndrome	0.000376	0.00623	CcSEcCtD
Paliperidone—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000346	0.029	CbGeAlD
Paliperidone—Asthenia—Metformin—polycystic ovary syndrome	0.000341	0.00566	CcSEcCtD
Paliperidone—Pruritus—Metformin—polycystic ovary syndrome	0.000336	0.00558	CcSEcCtD
Paliperidone—Diarrhoea—Metformin—polycystic ovary syndrome	0.000325	0.00539	CcSEcCtD
Paliperidone—Dizziness—Metformin—polycystic ovary syndrome	0.000314	0.00521	CcSEcCtD
Paliperidone—ADRA2C—endometrium—polycystic ovary syndrome	0.000309	0.0259	CbGeAlD
Paliperidone—HTR1B—endocrine gland—polycystic ovary syndrome	0.000305	0.0256	CbGeAlD
Paliperidone—Vomiting—Metformin—polycystic ovary syndrome	0.000302	0.00501	CcSEcCtD
Paliperidone—Rash—Metformin—polycystic ovary syndrome	0.0003	0.00497	CcSEcCtD
Paliperidone—Dermatitis—Metformin—polycystic ovary syndrome	0.0003	0.00497	CcSEcCtD
Paliperidone—Headache—Metformin—polycystic ovary syndrome	0.000298	0.00494	CcSEcCtD
Paliperidone—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000292	0.0245	CbGeAlD
Paliperidone—DRD2—pituitary gland—polycystic ovary syndrome	0.000287	0.0241	CbGeAlD
Paliperidone—HTR2A—embryo—polycystic ovary syndrome	0.000286	0.024	CbGeAlD
Paliperidone—ADRA2C—uterus—polycystic ovary syndrome	0.000284	0.0239	CbGeAlD
Paliperidone—HTR1A—adrenal gland—polycystic ovary syndrome	0.000284	0.0239	CbGeAlD
Paliperidone—Nausea—Metformin—polycystic ovary syndrome	0.000282	0.00468	CcSEcCtD
Paliperidone—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000279	0.0235	CbGeAlD
Paliperidone—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000278	0.0234	CbGeAlD
Paliperidone—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000262	0.022	CbGeAlD
Paliperidone—HRH1—endometrium—polycystic ovary syndrome	0.000251	0.0211	CbGeAlD
Paliperidone—ADRA2C—adrenal gland—polycystic ovary syndrome	0.00025	0.021	CbGeAlD
Paliperidone—HTR1A—endocrine gland—polycystic ovary syndrome	0.000246	0.0207	CbGeAlD
Paliperidone—ADRA2A—endometrium—polycystic ovary syndrome	0.000246	0.0207	CbGeAlD
Paliperidone—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000233	0.0196	CbGeAlD
Paliperidone—ADRA2C—female gonad—polycystic ovary syndrome	0.000233	0.0195	CbGeAlD
Paliperidone—ADRA2C—vagina—polycystic ovary syndrome	0.000231	0.0194	CbGeAlD
Paliperidone—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000227	0.0191	CbGeAlD
Paliperidone—ADRA2A—uterus—polycystic ovary syndrome	0.000227	0.0191	CbGeAlD
Paliperidone—HRH1—adipose tissue—polycystic ovary syndrome	0.000226	0.019	CbGeAlD
Paliperidone—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000223	0.0187	CbGeAlD
Paliperidone—DRD2—endocrine gland—polycystic ovary syndrome	0.000223	0.0187	CbGeAlD
Paliperidone—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000222	0.0186	CbGeAlD
Paliperidone—HRH1—adrenal gland—polycystic ovary syndrome	0.000203	0.017	CbGeAlD
Paliperidone—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000199	0.0167	CbGeAlD
Paliperidone—CYP3A5—female gonad—polycystic ovary syndrome	0.000195	0.0164	CbGeAlD
Paliperidone—CYP3A5—vagina—polycystic ovary syndrome	0.000194	0.0163	CbGeAlD
Paliperidone—HTR2A—pituitary gland—polycystic ovary syndrome	0.00019	0.0159	CbGeAlD
Paliperidone—HRH1—female gonad—polycystic ovary syndrome	0.000189	0.0159	CbGeAlD
Paliperidone—HRH1—vagina—polycystic ovary syndrome	0.000188	0.0158	CbGeAlD
Paliperidone—ADRA2A—female gonad—polycystic ovary syndrome	0.000186	0.0156	CbGeAlD
Paliperidone—ADRA2A—vagina—polycystic ovary syndrome	0.000185	0.0155	CbGeAlD
Paliperidone—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000181	0.0152	CbGeAlD
Paliperidone—HRH1—endocrine gland—polycystic ovary syndrome	0.000176	0.0148	CbGeAlD
Paliperidone—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000173	0.0145	CbGeAlD
Paliperidone—HTR2A—adrenal gland—polycystic ovary syndrome	0.000169	0.0142	CbGeAlD
Paliperidone—HTR2A—vagina—polycystic ovary syndrome	0.000157	0.0132	CbGeAlD
Paliperidone—HTR2A—endocrine gland—polycystic ovary syndrome	0.000147	0.0123	CbGeAlD
Paliperidone—CYP2D6—female gonad—polycystic ovary syndrome	0.000144	0.0121	CbGeAlD
Paliperidone—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000136	0.0114	CbGeAlD
Paliperidone—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000134	0.0112	CbGeAlD
Paliperidone—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.32e-06	3.61e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.32e-06	3.61e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—GNAS—polycystic ovary syndrome	6.32e-06	3.61e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.29e-06	3.59e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.29e-06	3.59e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.28e-06	3.59e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.28e-06	3.59e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6.27e-06	3.58e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.27e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	6.24e-06	3.56e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	6.22e-06	3.55e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	6.21e-06	3.55e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	6.19e-06	3.54e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.18e-06	3.53e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	6.18e-06	3.53e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	6.17e-06	3.53e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.17e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.15e-06	3.51e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.12e-06	3.49e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IRS2—polycystic ovary syndrome	6.1e-06	3.48e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	6.09e-06	3.48e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.05e-06	3.46e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	6.05e-06	3.46e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.03e-06	3.44e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.02e-06	3.44e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	6e-06	3.43e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IRS1—polycystic ovary syndrome	5.99e-06	3.42e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	5.99e-06	3.42e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	5.98e-06	3.42e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	5.97e-06	3.41e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	5.96e-06	3.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	5.95e-06	3.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	5.94e-06	3.39e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	5.93e-06	3.39e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	5.91e-06	3.38e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	5.87e-06	3.35e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.85e-06	3.34e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	5.83e-06	3.33e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	5.83e-06	3.33e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	5.77e-06	3.3e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	5.76e-06	3.29e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	5.76e-06	3.29e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.75e-06	3.29e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.75e-06	3.29e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	5.74e-06	3.28e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	5.73e-06	3.28e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	5.72e-06	3.27e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	5.72e-06	3.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	5.71e-06	3.26e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	5.64e-06	3.22e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	5.64e-06	3.22e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	5.63e-06	3.22e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.63e-06	3.21e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	5.61e-06	3.21e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	5.55e-06	3.17e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.55e-06	3.17e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	5.55e-06	3.17e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	5.51e-06	3.15e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.47e-06	3.13e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.46e-06	3.12e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.45e-06	3.11e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	5.45e-06	3.11e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	5.45e-06	3.11e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.4e-06	3.08e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	5.39e-06	3.08e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.36e-06	3.06e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.36e-06	3.06e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	5.35e-06	3.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.35e-06	3.06e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	5.32e-06	3.04e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.32e-06	3.04e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	5.29e-06	3.02e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.27e-06	3.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	5.25e-06	3e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.25e-06	3e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.24e-06	3e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	5.24e-06	3e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	5.22e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	5.2e-06	2.97e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	5.2e-06	2.97e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	5.17e-06	2.96e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	5.17e-06	2.95e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	5.17e-06	2.95e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	5.16e-06	2.95e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	5.14e-06	2.94e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—INS—polycystic ovary syndrome	5.14e-06	2.94e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	5.13e-06	2.93e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.13e-06	2.93e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	5.1e-06	2.91e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	5.06e-06	2.89e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	5.03e-06	2.88e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	5e-06	2.86e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.99e-06	2.85e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.98e-06	2.84e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.97e-06	2.84e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.96e-06	2.84e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	4.95e-06	2.83e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	4.93e-06	2.82e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	4.93e-06	2.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.88e-06	2.79e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.84e-06	2.77e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	4.81e-06	2.75e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	4.81e-06	2.75e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.75e-06	2.71e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.68e-06	2.68e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.67e-06	2.67e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.64e-06	2.65e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	4.63e-06	2.64e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	4.62e-06	2.64e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	4.6e-06	2.63e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.59e-06	2.62e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.58e-06	2.62e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.57e-06	2.61e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	4.57e-06	2.61e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.55e-06	2.6e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.5e-06	2.57e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.49e-06	2.57e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	4.49e-06	2.57e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	4.48e-06	2.56e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	4.47e-06	2.55e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.45e-06	2.54e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.45e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	4.45e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	4.44e-06	2.54e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.42e-06	2.53e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	4.42e-06	2.53e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	4.42e-06	2.52e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	4.41e-06	2.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	4.4e-06	2.51e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	4.32e-06	2.47e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.31e-06	2.46e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	4.3e-06	2.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.3e-06	2.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.3e-06	2.45e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	4.28e-06	2.44e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	4.27e-06	2.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.27e-06	2.44e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	4.26e-06	2.43e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	4.26e-06	2.43e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	4.25e-06	2.43e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	4.23e-06	2.42e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.23e-06	2.42e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	4.2e-06	2.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.18e-06	2.39e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—INS—polycystic ovary syndrome	4.18e-06	2.39e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	4.16e-06	2.38e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	4.16e-06	2.37e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.1e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.09e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.09e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.09e-06	2.34e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.08e-06	2.33e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	4.07e-06	2.33e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	4.06e-06	2.32e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.06e-06	2.32e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.05e-06	2.31e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.01e-06	2.29e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	4e-06	2.29e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.95e-06	2.26e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.93e-06	2.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	3.92e-06	2.24e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	3.9e-06	2.23e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	3.9e-06	2.23e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.89e-06	2.22e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.87e-06	2.21e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	3.86e-06	2.21e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	3.85e-06	2.2e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	3.85e-06	2.2e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	3.84e-06	2.19e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	3.83e-06	2.19e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—INS—polycystic ovary syndrome	3.83e-06	2.19e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.82e-06	2.18e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.82e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	3.78e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.77e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	3.77e-06	2.15e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.77e-06	2.15e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.76e-06	2.15e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.76e-06	2.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	3.76e-06	2.15e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.71e-06	2.12e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.71e-06	2.12e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.71e-06	2.12e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.7e-06	2.12e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.69e-06	2.11e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.67e-06	2.1e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.65e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.64e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.63e-06	2.08e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.63e-06	2.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.58e-06	2.05e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.53e-06	2.01e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.52e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	3.51e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	3.49e-06	2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.42e-06	1.96e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.4e-06	1.95e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.38e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.38e-06	1.93e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.29e-06	1.88e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	3.27e-06	1.87e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.26e-06	1.87e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.26e-06	1.86e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.22e-06	1.84e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.21e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	3.18e-06	1.82e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.17e-06	1.81e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.13e-06	1.79e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.98e-06	1.7e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.91e-06	1.66e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.89e-06	1.65e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.84e-06	1.62e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.83e-06	1.62e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.81e-06	1.6e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.79e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.78e-06	1.59e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.78e-06	1.59e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.74e-06	1.56e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.72e-06	1.55e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.72e-06	1.55e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.67e-06	1.53e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.66e-06	1.52e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	2.6e-06	1.49e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.58e-06	1.48e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.55e-06	1.46e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.53e-06	1.45e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	2.51e-06	1.43e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.46e-06	1.41e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.43e-06	1.39e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.42e-06	1.38e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.4e-06	1.37e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.37e-06	1.36e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	2.26e-06	1.29e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.24e-06	1.28e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	2.23e-06	1.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.21e-06	1.26e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.01e-06	1.15e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.94e-06	1.11e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.93e-06	1.1e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.88e-06	1.07e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.85e-06	1.06e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.81e-06	1.04e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.79e-06	1.02e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.78e-06	1.02e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	9.74e-06	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.68e-06	9.58e-06	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	1.67e-06	9.56e-06	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.64e-06	9.38e-06	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.53e-06	8.72e-06	CbGpPWpGaD
